TY - JOUR
T1 - Betulinic acid-nucleoside hybrid prevents acute alcohol -induced liver damage by promoting anti-oxidative stress and autophagy
AU - Zheng, Li yun
AU - Zou, Xi
AU - Wang, Yan li
AU - Zou, Min
AU - Ma, Fang
AU - Wang, Ning
AU - Li, Jia wen
AU - Wang, Ming sheng
AU - Hung, Hsin Yi
AU - Wang, Qiang
N1 - Funding Information:
This research was funded by the Basal Research Fund of the National Health Commission Key Laboratory of Birth Defect Prevention ( JBKY2020011 , JBKY2020012 ), the Medical Science and Technology Research Project of Henan Province ( LHGJ20190825 , LHGJ20190829 ), the Project of Basal Research Fund of Henan Institute of Medical and Pharmacological Sciences ( 2020BP0101 ), the Basal Research Fund of Henan Academy of Sciences ( 210602006 ).
Publisher Copyright:
© 2021 The Authors
PY - 2022/1/5
Y1 - 2022/1/5
N2 - Alcoholic abuse is one of the most serious causes of liver diseases worldwide. Although detailed molecular pathogenesis of alcohol-induced liver damages remains elusive with intensive debates, it has been widely recognized that hepatic damage caused by free radicals generated from alcohol metabolism is one of the most critical factors for alcohol-induced liver diseases. Betulinic acid is a potent antioxidant with additional known pharmacological safety characteristics and minimal toxicity. However, poor solubility limited its usage. In this study, we assessed the efficacy of BAN, a betulinic acid and nucleoside hybrid with good water solubility, in reversing acute liver damages using an established alcohol overdose animal model. The results indicated that BAN is an extremely promising therapeutic agent against acute alcohol-induced liver damage. BAN effectively protects liver from alcohol damage by reducing serum ALT level by up to 47%, as well as liver oxidative stress indicated by significantly increased SOD, CAT, and GSH-Px levels. Moreover, hepatic FXR activation and a corresponding downstream anti-oxidative stress transcriptional cascade including Nrf2, HO-1, and NOQ1 induce the protective role of BAN. On the other hand, BAN administration also leads to increase cellular autophagy response, as indicated by the key ATG protein activation. We concluded that BAN, comparing with Betulinic acid, prevents acute alcohol-induced liver damages more effectively, with the dual mechanisms of neutralizing oxidative stress and promoting autophagy.
AB - Alcoholic abuse is one of the most serious causes of liver diseases worldwide. Although detailed molecular pathogenesis of alcohol-induced liver damages remains elusive with intensive debates, it has been widely recognized that hepatic damage caused by free radicals generated from alcohol metabolism is one of the most critical factors for alcohol-induced liver diseases. Betulinic acid is a potent antioxidant with additional known pharmacological safety characteristics and minimal toxicity. However, poor solubility limited its usage. In this study, we assessed the efficacy of BAN, a betulinic acid and nucleoside hybrid with good water solubility, in reversing acute liver damages using an established alcohol overdose animal model. The results indicated that BAN is an extremely promising therapeutic agent against acute alcohol-induced liver damage. BAN effectively protects liver from alcohol damage by reducing serum ALT level by up to 47%, as well as liver oxidative stress indicated by significantly increased SOD, CAT, and GSH-Px levels. Moreover, hepatic FXR activation and a corresponding downstream anti-oxidative stress transcriptional cascade including Nrf2, HO-1, and NOQ1 induce the protective role of BAN. On the other hand, BAN administration also leads to increase cellular autophagy response, as indicated by the key ATG protein activation. We concluded that BAN, comparing with Betulinic acid, prevents acute alcohol-induced liver damages more effectively, with the dual mechanisms of neutralizing oxidative stress and promoting autophagy.
UR - http://www.scopus.com/inward/record.url?scp=85120620892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120620892&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2021.174686
DO - 10.1016/j.ejphar.2021.174686
M3 - Article
C2 - 34883073
AN - SCOPUS:85120620892
SN - 0014-2999
VL - 914
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
M1 - 174686
ER -